Research programme: cancer therapeutics - Intezyne

Drug Profile

Research programme: cancer therapeutics - Intezyne

Alternative Names: Daunorubicin - Intezyne; Epithilone-D - Intezyne; IT-121; IT-143; IT-145; IT-147

Latest Information Update: 22 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intezyne
  • Class Alkaloids; Anthracyclines; Camptothecins; Gene therapies; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA intercalators; DNA topoisomerase I inhibitors; Gene transference; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 22 Nov 2017 Preclinical development is ongoing in USA (Intezyne pipeline, November 2017)
  • 22 Nov 2017 Cancer therapeutics - Intezyne is available for licensing as of 15 Nov 2017.
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top